5-year outcomes of CheckMate 9LA study

Prof Christophe Dooms, thoracic oncologist at UZ Leuven and Prof Martin Reck, thoracic oncologist and Head of the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, Hamburg, Germany, discuss the five-year outcomes of the CheckMate 9LA study. This study evaluates the efficacy of first-line treatment with nivolumab plus ipilimumab combined with chemotherapy versus chemotherapy alone in patients with mNSCLC. The findings indicate a significant long-term, durable survival benefit for patients treated with the combination therapy, particularly in those with tumour PD-L1 expression < 1% or with squamous histology. These results further establish the combination of ipilimumab, nivolumab, and chemotherapy as an efficacious first-line treatment option for mNSCLC patients.